UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

Lantern Pharma Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share (Title of Class of Securities)

> 51654W101 (CUSIP Number)

Bios Equity Partners, LP 1751 River Run, Suite 400 Fort Worth, Texas Tel: (817) 984-9197

With a Copy to: Rick Jordan Polsinelli PC 2950 Harwood St., Suite 2100 Dallas, Texas 75201 Tel: (214) 397-0030

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 28, 2024 (Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	AE OF REPORTING PERSONS				
	DS FUND I, LP				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) \Box (b) \boxtimes				
3	SEC USE ONLY				
4	SOURCE OF FUNDS				
	WC				
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)				
6	CITIZENSHIP OR PLACE OF ORGANIZATION				
	DELAWARE, UNITED STATES				
N	JMBER OF 7 SOLE VOTING POWER				
	SHARES -0-				
	WNED BY				

EACH		8	SHARED VOTING POWER			
REPORTING						
	PERSON		371,950 (1)			
	WITH	9	SOLE DISPOSITIVE POWER			
			-0-			
		10	SHARED DISPOSITIVE POWER			
			371,950 (1)			
11	AGGREGAT	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	371,950(1)					
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES					
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)					
	3.5% (2)					
14	TYPE OF REPORTING PERSON					
	PN					

Consists of 371,950 shares of common stock of the Issuer, par value \$0.0001 per share ("Shares") directly held by Bios Fund I, LP ("Bios Fund I") as of the date hereof.
Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer's quarterly report on Form 10-Q filed with the Saverities and Long Law Parts (ii) 145,248 Shares are purpleted in the Issuer's quarterly report on Form 10-Q filed with the Saverities and Long Law Parts (iii) 145,248 Shares are purpleted in the Issuer's quarterly report on Form 10-Q filed with the Saverities and Long Law Parts (iii) 145,248 Shares are purpleted in the Issuer's quarterly report on Form 10-Q filed with the Saverities and Long Law Parts (iii) 145,248 Shares are purpleted in the Issuer's quarterly report on Form 10-Q filed with the Saverities and Long Law Parts (iii) 145,248 Shares are purpleted in the Issuer's quarterly report on Form 10-Q filed with the Saverities and Long Law Parts (iii) 145,248 Shares are purpleted in the Issuer's quarterly report on Form 10-Q filed with the Saverities and Long Law Parts (iii) 145,248 Shares are purpleted in the Issuer's quarterly report on Form 10-Q filed with the Saverities and Long Law Parts (iii) 145,248 Shares are purpleted in the Issuer's quarterly report on Form 10-Q filed with the Issuer's quarterly report on Form 10-Q filed with the Issuer's quarterly report on Form 10-Q filed with the Issuer's quarterly report on Form 10-Q filed with the Issuer's quarterly report on Form 10-Q filed with the Issuer's quarterly report on Form 10-Q filed with the Issuer's quarterly report on Form 10-Q filed with the Issuer's quarterly report on Form 10-Q filed with the Issuer's quarterly report on Form 10-Q filed with the Issuer's quarterly report on Form 10-Q filed with the Issuer's quarterly report on Form 10-Q filed with the Issuer's quarterly report on Form 10-Q filed with the Issuer's quarterly report on Form 10-Q filed with the Issuer's quarterly report on Fo

Securities and Exchange Commission on November 8, 2023, *minus* (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP, LP ("Bios Fund I QP") on November 21, 2023, *plus* (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II") and Bios Fund II NT, LP ("Bios Fund II"), Diss Fund II QP, LP ("Bios Fund II"), CP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II"), Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II"), Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II"), Bios Fund II"), Bios Fund II", LP ("Bios Fund II"), Bios Fund II"), Bios Fund II", LP ("Bios Fund II"), Bios Fund II"), Bios Fund II"), Bios Fund II", LP ("Bios Fund II"), Bios Fund II"), Bios Fund II"), Bios Fund II", LP ("Bios Fund II"), Bios Fund II", LP ("Bios Fund II"), Bios Fund

CUSIP No. 51654W101

1	NAME OF REPORTING PERSONS						
	BIOS FUND I QP, LP						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP						
2	(a) \Box (b) \boxtimes						
	(0) = (0) =						
3	SEC USE ON	JLY					
4	SOURCE OF	FUND	NS				
	WC						
5		(IF DI	SCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)				
5	enileit boi						
6	CITIZENSHI	P OR F	PLACE OF ORGANIZATION				
	DELAWARE	5, UNIT 7	ED STATES SOLE VOTING POWER				
	MBER OF	/	SOLE VOTING POWER				
	SHARES		-0-				
	EFICIALLY WNED BY	8	SHARED VOTING POWER				
0	EACH						
RE	PORTING	_	217,553 (1)				
1	PERSON	9	SOLE DISPOSITIVE POWER				
	WITH		-0-				
		10	SHARED DISPOSITIVE POWER				
			217,553 (1)				
11	AGGREGAT	Έ AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	217 552 (1)						
12	217,553 (1)	IF TH	IE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES				
12	, UNEUR DUA IF THE AUUKEUATE AWUUNT IN KUW (11) EAULUDES UERTAIN SHAKES						
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)						
	2.0% (2)						
14	TYPE OF RE	PORT	ING PERSON				
	PN						

(1) Consists of 217,553 Shares directly held by Bios Fund I QP as of the date hereof.

(2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, *minus* (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, *plus* (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

1	NAME OF REPORTING PERSONS				
	BIOS FUND II, LP				
2		PRIAT	E BOX IF A MEMBER OF A GROUP		
	(a) □ (b) ⊠				
3	SEC USE ONLY				
4	SOURCE OF FUNDS				
	WG				
5	WC CHECK BOX IF DISC		IRE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)		
5	CHECK BOX IF DISC	LUSC	RE OF LEGAL I ROCEEDINGS IS REQUIRED I ORSOANT TO TTEM 2(d) OR 2(c)		
6	CITIZENSHIP OR PL	ACE O	FORGANIZATION		
	DELAWARE, UNITE		TEQ		
		7	SOLE VOTING POWER		
	NUMBER OF	/	SOLE VOTING FOWER		
	SHARES BENEFICIALLY		-0-		
	OWNED BY	8	SHARED VOTING POWER		
	EACH				
	REPORTING	9	137,832 (1) SOLE DISPOSITIVE POWER		
	PERSON	9	SOLE DISPOSITIVE FOWER		
	WITH		-0-		
		10	SHARED DISPOSITIVE POWER		
			137,832 (1)		
11	AGGREGATE AMOU	JNT B	ENEFICIALLY OWNED BY EACH REPORTING PERSON		
10	137,832 (1)				
12	CHECK BOX IF THE	AGGI	REGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		
13	PERCENT OF CLASS	S REPH	RESENTED BY AMOUNT IN ROW (11)		
	1 20/ (2)				
14	1.3% (2) TYPE OF REPORTIN	IG PER	NON		
17	+ TITE OF KEFOKTINU FEKJON				
	PN				
	•				

(1) Consists of 137,832 Shares directly held by Bios Fund II as of the date hereof.

(2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, *minus* (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, *plus* (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

1	NAME OF REPORTING PERSONS					
	BIOS FUND II QP, LI					
2		PRIAT	E BOX IF A MEMBER OF A GROUP			
	(a) \Box (b) \boxtimes	$(a) \Box (b) \boxtimes$				
3	SEC USE ONLY					
L						
4	SOURCE OF FUNDS	JNDS				
	WC					
-						
5	CHECK BOX IF DISC.	LOSUR	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)			
6	CITIZENSHIP OR PLA					
0	CITIZENSIIII OKTEP	ACE OF	LE OF ORGANIZATION			
	DELAWARE, UNITED	DELAWARE, UNITED STATES				
	, =,	7	SOLE VOTING POWER			
	NUMBER OF	'	SOLE VOTING FOWER			
	SHARES		-0-			
	BENEFICIALLY	8	SHARED VOTING POWER			
	OWNED BY	0	SHARED VOTINGTOWER			
	EACH		450,118 (1)			
	REPORTING PERSON	9	SOLE DISPOSITIVE POWER			
	WITH					
	YV 1 1 1 1		-0-			
1						

	10 SHARED DISPOSITIVE POWER
	450,118 (1)
1.1	
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	450,118 (1)
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	4.2% (2)
14	TYPE OF REPORTING PERSON
1.	
	PN

(1) Consists of 450,118 Shares directly held by Bios Fund II QP as of the date hereof.

Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, *minus* (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, *plus* (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

CUSIP No. 51654W101

1	NAME OF REPORTING PERSONS				
	BIOS FUND II NT, LP				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) □ (b) ⊠				
	(a) L (b) 🖾				
3	SEC USE ONLY	SEC USE ONLY			
4	SOURCE OF FUNDS				
	WC				
5	CHECK BOX IF DISC	CLOSU	JRE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)		
6	CITIZENSHIP OR PL	ACE C	OF ORGANIZATION		
	DELAWARE, UNITE	D STA	ATES		
	NUMBER OF	7	SOLE VOTING POWER		
	SHARES BENEFICIALLY		-0-		
	OWNED BY	8	SHARED VOTING POWER		
EACH					
	REPORTING PERSON	9	SOLE DISPOSITIVE POWER		
	WITH		-0-		
		10	SHARED DISPOSITIVE POWER		
			60,256 (1)		
11	AGGREGATE AMOU	JNT B	ENEFICIALLY OWNED BY EACH REPORTING PERSON		
	60,256 (1)				
12					
13	PERCENT OF CLASS	S REPI	RESENTED BY AMOUNT IN ROW (11)		
	0.6% (2)				
14	TYPE OF REPORTIN	IG PER	RSON		
	PN				

(1) Consists of 60,256 Shares directly held by Bios Fund II NT as of the date hereof.

(2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, *minus* (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, *plus* (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

1	NAME OF REPORTING PERSONS				
	BP DIRECTORS, LP				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) □ (b) ⊠				
3	SEC USE ONLY				
4	SOURCE OF FUNDS				
	00				
5	CHECK BOX IF DISC	CLOSU	JRE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)		
6	CITIZENSHIP OR PL	ACE 0	DF ORGANIZATION		
	DELAWARE, UNITE	D STA	ATES		
	NUMBER OF	7	SOLE VOTING POWER		
	SHARES		-0-		
	BENEFICIALLY OWNED BY	8	SHARED VOTING POWER		
	EACH		26,093 (1)		
	REPORTING PERSON		SOLE DISPOSITIVE POWER		
	WITH		-0-		
		10	SHARED DISPOSITIVE POWER		
			26,093 (1)		
11	AGGREGATE AMOU	JNT B	ENEFICIALLY OWNED BY EACH REPORTING PERSON		
	26,093 (1)				
12		AGG	REGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		
13		S REPI	RESENTED BY AMOUNT IN ROW (11)		
	0.2% (2)				
14	TYPE OF REPORTIN	G PEF	RSON		
	PN				
L	111				

(1) Consists of 26,093 Shares directly held by BP Directors, LP ("Bios Directors") as of the date hereof.

(2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, *minus* (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, *plus* (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

1	NAME OF REPORTING PERSONS						
	BIOS EQUITY PARTNERS, LP						
2	CHECK THE	E APP	ROPRIATE BOX IF A MEMBER OF A GROUP				
	(a) \Box (b) \boxtimes						
3	SEC USE ON	JLY					
-							
4	SOURCE OF	FUN	80				
-	SOURCE OF	1010					
	AF						
5			ISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)				
5	CHECK BUZ	A IF D	ISCLOSURE OF LEGAL FROCEEDINGS IS REQUIRED FORSUANT TOTTEM 2(d) OR 2(e)				
6							
6 CITIZENSHIP OR PLACE OF ORGANIZATION							
	TEXAC IN						
	TEXAS, UN	TED	STATES				
		7	SOLE VOTING POWER				
	JMBER OF						
	SHARES		-0-				
	NEFICIALLY	8	SHARED VOTING POWER				
OWNED BY		0					
	EACH		615,596 (1)				
	EPORTING	9	SOLE DISPOSITIVE POWER				
	PERSON		SOLE DISTOSTITUET OWER				
	WITH		-0-				
			-0-				
1		1					

	10 SHARED DISPOSITIVE POWER				
	615,596 (1)				
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	615,596 (1)				
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES				
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)				
15	TERCENT OF CEASE RESERTED OF MICONT IN ROW (II)				
	5.7% (2)				
14	TYPE OF REPORTING PERSON				
17					
	PN				
L					

- (1) Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP and (iii) 26,093 Shares directly held by Bios Directors, in each case, as of the date hereof. Bios Equity Partners, LP ("Bios Equity I") is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. In its capacity as the general partner of these entities, Bios Equity I may be deemed to have shared voting and/or dispositive power with respect to Shares directly held by these entities.
- (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, *minus* (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, *plus* (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

1	NAME OF REPORTING PERSONS						
		BIOS EQUITY PARTNERS II, LP					
2		PRIAT	E BOX IF A MEMBER OF A GROUP				
	(a) □ (b) ⊠						
3	SEC USE ONLY						
4	SOURCE OF FUNDS						
	AF						
5	CHECK BOX IF DISC	LOSU	RE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)				
	_						
6	CITIZENSHIP OR PLA	ACE O	F ORGANIZATION				
		TEC					
	TEXAS, UNITED STA						
	NUMBER OF	7	SOLE VOTING POWER				
	SHARES						
	BENEFICIALLY		-0-				
	OWNED BY	8	SHARED VOTING POWER				
	EACH						
	REPORTING		648,206 (1)				
	PERSON	9	SOLE DISPOSITIVE POWER				
	WITH						
		10	-0- SHARED DISPOSITIVE POWER				
		10	SHARED DISPOSITIVE POWER				
			648,206 (1)				
11			ENEFICIALLY OWNED BY EACH REPORTING PERSON				
11	AGGREGATE AMOU	JNI B	ENEFICIALLY OWNED BY EACH KEPOKTING PEKSON				
	648,206 (1)						
12		ACCI	REGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES				
12	CHECK DUA IF THE	AUUI	AEGATE AMOUNT IN NOW (11) EACLUDES CERTAIN SHAKES				
13		REPR	RESENTED BY AMOUNT IN ROW (11)				
15	I ERCENT OF CLASS	, IVELLE					
	6.0% (2)						
14	TYPE OF REPORTIN	G PER	SON				
1							
	PN						
L							

- (1) Consists of (i) 137,832 Shares directly held by Bios Fund II, (ii) 450,118 Shares directly held by Bios Fund II QP and (iii) 60,256 Shares directly held by Bios Fund II NT, in each case, as of the date hereof. Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. In its capacity as the general partner of these entities, Bios Equity II may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly held by these entities.
- (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, *minus* (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, *plus* (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

r					
1	NAME OF REPORTING PERSONS				
	CAVU MANAGEMENT, LP				
2		PRIAT	E BOX IF A MEMBER OF A GROUP		
	(a) □ (b) ⊠				
3	SEC USE ONLY				
_					
4	SOURCE OF FUNDS				
	AF				
5		CLOSU	IRE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)		
	_				
6	CITIZENSHIP OR PL	ACEC			
0	CITIZENSHIF OK FL	ACE	JF ORDANIZATION		
	TEXAS, UNITED ST.	ATES			
	NUMBER OF	7	SOLE VOTING POWER		
	SHARES		-0-		
	BENEFICIALLY OWNED BY	8	SHARED VOTING POWER		
	EACH				
	REPORTING	9	1,263,802 (1) SOLE DISPOSITIVE POWER		
	PERSON WITH	9	SOLE DISPOSITIVE POWER		
	WIIH		-0-		
		10	SHARED DISPOSITIVE POWER		
			1,263,802 (1)		
11	AGGREGATE AMO	UNT B	ENEFICIALLY OWNED BY EACH REPORTING PERSON		
11	1,263,802 (1)				
12		E AGGI	REGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		
12					
	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)				
13					
	11.8% (2)				
14	TYPE OF REPORTIN	NG PEF	(SOIN		
	PN				

- (1) Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II. Cavu Management may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I, Bios Fund II, Bios Fund II, Bios Fund II, QP, Bios Fund II QP, Bios Fund II NT and Bios Directors.
- (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, *minus* (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, *plus* (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

1	NAME OF REPORTING PERSONS			
	BIOS CAPITAL MANAGEMENT, LP			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			
	(a) □ (b) ⊠			
2	OF CLUE ONLY			
3	3 SEC USE ONLY			
4	SOURCE OF FUNDS			
	AF			
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)			
6	CITIZENSHIP OR PLACE OF ORGANIZATION			
	TEXAS, UNITED STATES			
	NUMBER OF	7 SOLE VOTING POWER		
	SHARES			
		-0-		
	BENEFICIALLY	· · ·		
1	OWNED BY			

	EACH	8	SHARED VOTING POWER	
REPORTING				
PERSON			1,263,802 (1)	
	WITH	9	SOLE DISPOSITIVE POWER	
			-0-	
		10	SHARED DISPOSITIVE POWER	
			1,263,802 (1)	
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	1,263,802 (1)			
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES			
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)			
	11.8% (2)			
14	TYPE OF REPORTING PERSON			
	PN			

(1) Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II QP and Bios Fund II NT. Bios Capital Management, LP ("Bios Management") is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Bios Management may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I, QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Directors.

(2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, *minus* (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, *plus* (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

1	NAME OF REPORTING PERSONS						
	CAVU ADVISORS, LLC						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP						
	$(a) \Box (b) \boxtimes$						
3	SEC USE ON	LY					
4	SOURCE OF FUNDS						
	AF						
5	CHECK BOX	K IF D	ISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)				
6	CITIZENSHI	P OR	PLACE OF ORGANIZATION				
	TEXAS, UNI	TED					
	JMBER OF	7	SOLE VOTING POWER				
	SHARES VEFICIALLY		-0-				
	WNED BY EACH EPORTING PERSON WITH	8	SHARED VOTING POWER				
RE			1,263,802 (1)				
]		9	SOLE DISPOSITIVE POWER				
			-0-				
		10	SHARED DISPOSITIVE POWER				
		1,263,802 (1)					
11	AGGREGAT	'E AM	IOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
10	1,263,802 (1)						
12	2 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES						
13		ECI					
13	B PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)						
14	11.8% (2) 4 TYPE OF REPORTING PERSON						
14	I I PE OF RE	POK					
	00						

- (1) Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II QP and Bios Equity II. Cavu Advisors, LLC ("Cavu Advisors") is the general partner of Cavu Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Directors.
- (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, *minus* (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, *plus* (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

1	NAME OF REPORTIN	NG PE	RSONS		
	BIOS ADVISORS GP, LLC				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) □ (b) ⊠				
3	SEC USE ONLY				
4	SOURCE OF FUNDS				
5	AF		THE OF LECAL INDOCEDNICS IS DECLIDED NURSHANT TO ITEM 3(4) OD 2(.)		
3	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)				
6	CITIZENSHIP OR PL	ACE C)F ORGANIZATION		
	TEXAS, UNITED STA	ATES			
	NUMBER OF	7	SOLE VOTING POWER		
	SHARES				
	BENEFICIALLY				
	OWNED BY	8	SHARED VOTING POWER		
	EACH		1,263,802 (1)		
	REPORTING	9	SOLE DISPOSITIVE POWER		
	PERSON WITH	-			
	W1111		-0-		
		10	SHARED DISPOSITIVE POWER		
I			1,263,802 (1)		
11	AGGREGATE AMOU	UNT B	ENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1 2(2 802 (1)				
	1,263,802 (1)	AGGI	REGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		
12	CHECK DOA IF THE	, AUUI	ALGATE AMOUNT IN NOW (11) EACLUDES CERTAIN SHARES		
13	PERCENT OF CLASS	S REPF	RESENTED BY AMOUNT IN ROW (11)		
15					
	11.8% (2) TYPE OF REPORTIN	IC DED	SON		
14	1117E OF KEPOKTIN	NU PER			
	00				

- (1) Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II QP and Bios Equity I. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I, Bios Fund II, Bios Fund II QP, Bios Fund II QP, Bios Fund II NT and Bios Directors.
- (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, *minus* (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, *plus* (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

—	
1	NAME OF REPORTING PERSONS
	LESLIE WAYNE KREIS, JR.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
-	
	$(a) \Box (b) \boxtimes$

3	SEC USE ONLY						
4	SOURCE OF FUNDS						
	AF, OO						
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)						
6	CITIZENSHIP OR PLACE OF ORGANIZATION						
	UNITED STA	ATES					
N	UMBER OF	7	SOLE VOTING POWER				
BFI	SHARES NEFICIALLY		0				
	WNED BY	8	SHARED VOTING POWER				
R	EACH REPORTING PERSON		1,263,802 (1)				
			SOLE DISPOSITIVE POWER				
	WITH		0				
		10	SHARED DISPOSITIVE POWER				
			1,263,802 (1)				
11	AGGREGAT	E AM	IOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	1,263,802 (1)						
12	2 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES						
13	3 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)						
	11.8% (2)						
14	14 TYPE OF REPORTING PERSON						
	IN						

(1) Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund I QP and Bios Equity II. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I, Bios Fund I QP, Bios Fund II, DP, Bios Fund II NT and Bios Directors.

(2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, *minus* (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, *plus* (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

1	NAME OF REPORTI	NG PE	RSONS	
	AARON GLENN LO	UIS FL	ETCHER	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			
	(a) □ (b) ⊠			
	(-) = (-) =			
3	SEC USE ONLY			
5				
4	SOURCE OF FUNDS			
	boonce of reneb			
	AF			
5	CHECK BOX IF DISC	CLOSU	JRE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)	
-				
6	CITIZENSHIP OR PLACE OF ORGANIZATION			
	UNITED STATES			
NUMBER OF 7 SOLE VOTING POWER			SOLE VOTING POWER	
	SHARES			
	BENEFICIALLY		-0-	
	OWNED BY	8	SHARED VOTING POWER	
	EACH			
	REPORTING PERSON		1,263,802 (1)	
			SOLE DISPOSITIVE POWER	
	WITH	1		
			-0-	
		10	SHARED DISPOSITIVE POWER	
		1		
			1,263,802 (1)	

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	1,263,802 (1)
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	11.8% (2)
14	TYPE OF REPORTING PERSON
	IN

- (1) Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund I QP and Bios Equity II. Bios Advisors, an entity controlled by Aaron Glenn Louis Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Mr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly need by Bios Fund I, Bios Fund II, Or Bios Fund II, Or Bios Fund II, Bio
- (2) Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, *minus* (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, *plus* (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

Item 1. SECURITY AND ISSUER

This Amendment No. 3 hereby amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission on June 15, 2020 (the "Original Schedule 13D"), as amended by the statement on Schedule 13D/A filed with the Securities and Exchange Commission on March 22, 2022 ("Amendment No. 1"), as further amended by the statement on Schedule 13D/A filed with the Securities and Exchange Commission on December 1, 2023 ("Amendment No. 2" and, together with the Original Schedule 13D and Amendment No. 1, the "Prior Statements"). The securities to which the Schedule 13D relates are the shares of common stock, par value \$0.0001 per share (the "Shares"), of Lantern Pharma, Inc., a Delaware corporation (the "Issuer").

The Purpose of this Amendment No. 3 is to disclose the sale of Shares by each of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II NT, LP ("Bios Fund II NT") on the open market. Except as otherwise provided herein, each Item of the Prior Statements remains unchanged. Capitalized terms used herein but not defined in this Amendment No. 3 shall have the meaning ascribed to such term in the Prior Statements.

Item 5. INTEREST IN SECURITIES OF THE ISSUER

Item 5 of the Schedule 13D is hereby amended and restated in its entirety to read as follows:

- (a) See rows (11) and (13) of the cover pages to this Amendment No. 3 for the aggregate number of Shares and percentages of the Shares beneficially owned by each of the Reporting Persons. See footnotes (1) and (2), as applicable, of the cover pages to this Amendment No. 3 for the calculations used in determining the percentages of Shares beneficially owned by each of the Reporting Persons.
- (b) See rows (7) through (10) of the cover pages to this Amendment No. 3 for the number of Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
- (c) On January 17, 2024, each of Bios Fund II NT, Bios Fund II QP and Bios Fund II exercised warrants to purchase 7,347, 54,873 and 16,801, respectively, shares of common stock of the Issuer. Each of Bios Fund II NT, Bios Fund II QP and Bios Fund II paid the exercise price on a cashless basis, resulting in the Issuer withholding 5,475, 40,893 and 12,521, respectively, of the warrant shares to pay the exercise price and issuing Bios Fund II NT, Bios Fund II the remaining 1,872, 13,980 and 4,280 shares respectively.

On February 27, 2024, each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold 4,649, 34,371 and 10,620, respectively, shares of common stock of the Issuer on the open market at a weighted average price of \$4.40. These shares were sold in multiple transactions ranging from \$4.35 to \$4.50. The Reporting Persons undertake to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

On February 28, 2024, each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold 6,909, 51,608 and 15,780, respectively, shares of common stock of the Issuer on the open market at a weighted average price of \$4.85. These shares were sold in multiple transactions ranging from \$4.60 to \$5.21. The Reporting Persons undertake to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

On February 29, 2024, each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold 1,832, 13,686 and 4,185, respectively, shares of common stock of the Issuer on the open market at a weighted average price of \$4.87. These shares were sold in multiple transactions ranging from \$4.62 to \$5.33. The Reporting Persons undertake to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

- (d) Except as described in this Amendment No. 3 to the knowledge of the Reporting Persons, only the reporting Persons have the right to receive or the power to direct receipt of dividends from, or proceeds from the sale of, the Shares reported by the Schedule 13D.
- (e) Not applicable.

Item 7. EXHIBITS

A Joint Filing Agreement, dated June 23, 2020 (incorporated by reference to the Original Schedule 13D, filed on June 23, 2020).

After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: March 1, 2024

BIOS FUND I, LP

By: Bios Equity Partners, LP, its general partner

By: Cavu Management, LP, its general partner

By: Cavu Advisors, LLC, its general partner

> By: <u>/s/ Daniel Schwarz</u> Daniel Schwarz Attorney-in-Fact

- By: Bios Capital Management, LP, its general partner
 - By: Bios Advisors GP, LLC, its general partner
 - By: <u>/s/ Daniel Schwarz</u> Daniel Schwarz Attorney-in-Fact

BIOS FUND I QP, LP

- By: Bios Equity Partners, LP, its general partner
 - By: Cavu Management, LP, its general partner
 - By: Cavu Advisors, LLC, its general partner
 - By: <u>/s/ Daniel Schwarz</u> Daniel Schwarz Attorney-in-Fact
 - By: Bios Capital Management, LP, its general partner
 - By: Bios Advisors GP, LLC, its general partner
 - By: <u>/s/ Daniel Schwarz</u> Daniel Schwarz
 - Attorney-in-Fact

BP DIRECTORS, LP

- By: Bios Equity Partners, LP, its general partner
 - By: Cavu Management, LP, its general partner
 - By: Cavu Advisors, LLC, its general partner

By: /s/ Daniel Schwarz

Daniel Schwarz Attorney-in-Fact

By: Bios Capital Management, LP,

its general partner

By: Bios Advisors GP, LLC, its general partner

By: /s/ Daniel Schwarz

Daniel Schwarz Attorney-in-Fact

BIOS FUND II, LP

- By: Bios Equity Partners II, LP, its general partner
 - By: Cavu Management, LP, its general partner
 - By: Cavu Advisors, LLC, its general partner
 - By: <u>/s/ Daniel Schwarz</u> Daniel Schwarz Attorney-in-Fact
 - By: Bios Capital Management, LP, its general partner
 - By: Bios Advisors GP, LLC, its general partner
 - By: /s/ Daniel Schwarz Daniel Schwarz Attorney-in-Fact

BIOS FUND II QP, LP

- By: Bios Equity Partners II, LP, its general partner
 - By: Cavu Management, LP, its general partner
 - By: Cavu Advisors, LLC, its general partner
 - By: <u>/s/ Daniel Schwarz</u> Daniel Schwarz Attorney-in-Fact
 - By: Bios Capital Management, LP, its general partner
 - By: Bios Advisors GP, LLC, its general partner
 - By: <u>/s/ Daniel Schwarz</u> Daniel Schwarz Attorney-in-Fact

BIOS FUND II NT, LP

- By: Bios Equity Partners II, LP, its general partner
 - By: Cavu Management, LP, its general partner
 - By: Cavu Advisors, LLC, its general partner

By: <u>/s/ Daniel Schwarz</u> Daniel Schwarz

- Attorney-in-Fact
- By: Bios Capital Management, LP, its general partner
 - By: Bios Advisors GP, LLC, its general partner
 - By: <u>/s/ Daniel Schwarz</u> Daniel Schwarz Attorney-in-Fact

BIOS EQUITY PARTNERS, LP

By: Cavu Management, LP, its general partner

By: Cavu Advisors, LLC, its general partner

By: <u>/s/ Daniel Schwarz</u> Daniel Schwarz Attorney-in-Fact

By: Bios Capital Management, LP, its general partner

> By: Bios Advisors GP, LLC, its general partner

> > By: <u>/s/ Daniel Schwarz</u> Daniel Schwarz

Attorney-in-Fact

BIOS EQUITY PARTNERS II, LP

By: Cavu Management, LP, its general partner

By: Cavu Advisors, LLC, its general partner

By: <u>/s/ Daniel Schwarz</u> Daniel Schwarz Attorney-in-Fact

By: Bios Capital Management, LP, its general partner

By: Bios Advisors GP, LLC, its general partner

By: <u>/s/ Daniel Schwarz</u> Daniel Schwarz Attorney-in-Fact

CAVU MANAGEMENT, LP

By: Cavu Advisors, LLC, its general partner

By: <u>/s/ Daniel Schwarz</u> Daniel Schwarz Attorney-in-Fact

BIOS CAPITAL MANAGEMENT, LP

By: Bios Advisors GP, LLC its general partner

By: <u>/s/ Daniel Schwarz</u> Daniel Schwarz Attorney-in-Fact

CAVU ADVISORS, LLC

By: <u>/s/ Daniel Schwarz</u> Daniel Schwarz Attorney-in-Fact

BIOS ADVISORS GP, LLC

By: /s/ Daniel Schwarz

Daniel Schwarz

Attorney-in-Fact

/s/ Daniel Schwarz

DANIEL SCHWARZ, as Attorney-in-Fact for Leslie Wayne Kreis, Jr.

/s/ Daniel Schwarz

DANIEL SCHWARZ, as Attorney-in-Fact for Aaron Glenn Louis Fletcher